Halaven Demonstrates Survival Benefit and Becomes First FDA-Approved Chemotherapy for Liposarcoma

Halaven Demonstrates Survival Benefit and Becomes First FDA-Approved Chemotherapy for Liposarcoma
According to a U.S. Food and Drug Administration (FDA) press release, the agency has just approved Halaven (eribulin mesylate) – a specific type of chemotherapy for the treatment of liposarcoma (a soft tissue sarcoma) that is in an advanced state (metastatic) or cannot be removed through surgery (unresectable). Furthermore, the chemotherapy is indicated for patients who received previous treatment containing an anthracycline drug. Liposarcoma is a particular kind of soft tissue sarcoma (STS) – a disease where cancer cells group in the soft tissues, such as tissues around joints, nerves, lymph vessels, blood vessels, fat, tendons or muscles – which occurs primarily in fat cells. In 2014, approximately 12,000 cases of STS are estimated to have been diagnosed in the U.S. alone, according to the National Cancer Institute. Halaven was evaluated for its safety and efficacy in 143 clinical trial participants with an advanced form of liposarcoma that had spread to surrounding lymph nodes (locally advanced), that was unresectable or that was metastatic and who had all been treated with chemotherapy. The trial was designed to measure the patients’ overall survival rate by being administered either Halaven or another chemo drug, dacarbazine. The median overall survival for liposarcoma patients that were given Halaven was significantly superior to dacarbazine, with 15.6 months over 8.4 months, respectively. “Halaven is the first drug approved for patients with liposarcoma that has demonstrated an improvement in survival time,” commented the Director of the FDA’s Office of He
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.